Novartis strengthens multiple sclerosis focus with the addition of Ofatumumab to leading MS portfolio which includes Gilenya and investigational treatments…
New analysis will confirm high efficacy of Gilenya® in achieving 'no evidence of disease activity' (NEDA4) in previously-treated highly-active RMS…